Professor Shenghua Zhou
The Second Xiangya Hospital of Central South University, Changsha (China)
Low-dose rivaroxaban during the acute phase of ACS - H-REPLACE Trial)
Event: ESC Congress 2021 - The Digital Experience
Topic: Pharmacotherapy
Session: Late Breaking Trials in ACS
ESC 365 is supported by
